Cencora Inc

Explore Cencora’s rising stock, robust pipeline and cost‑effective therapies, including FDA‑approved Product A, to boost patient outcomes and investor confidence.

Insider sale by Silvana Battaglia at Cencora Inc. reveals market sensitivity; 1.2 M shares sold at $45.30, sparking analyst debate on governance and investor confidence.

Insightful look at Cencora’s recent insider trades and analyst praise, showing how active governance and market positioning shape its health‑care competitiveness.

How Cencora’s $850 m OneOncology deal could boost oncology value‑based contracts, raise ARPP by 7% and add $120 m in annual cash flow while expanding 300 U.S. community sites.

Explore how Cencora’s $5 billion majority stake in OneOncology expands its oncology footprint and positions it for high‑margin growth in the cancer‑treatment market.

Explore Cencora’s FY‑2025 results: revenue up 9.6%, EPS 27% growth, and a 52‑week high driven by oncology and rare‑disease contracts—why investors stay bullish yet watch for next catalysts.

Explore why Cencora’s stock just hit a 52‑week high—its strong cash flow, service‑centric model, and growth‑oriented digital strategy suggest a buying window, yet regulatory and margin risks temper the upside.

Explore how Cencora Inc. maintains steady stock performance through diversified OTC and home‑healthcare solutions, outpacing peers in a shifting health‑care market.

Cencora Inc. has demonstrated a decade of outperformance, driven by its sustained investment in research and development, operational efficiency, and strategic partnerships, while the health-care sector is poised for continued growth, fueled by the …

Cencora Inc.’s stock price rises 1.98% on the NYSE, driven by a Relative Strength Rating upgrade and analyst sentiment, but a deeper analysis of the company’s financials and regulatory landscape reveals a more nuanced picture with both opportunities…